Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
AdHER2DC vaccine
Pembrolizumab
+3 more
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
May 14, 2024
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2028
Last Updated
April 9, 2026
NCT06257264
NCT06547840
NCT05489211
NCT04657068
NCT07029399
NCT04585750
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions